Adial Pharmaceuticals Stock Price Patterns
| ADIL Stock | USD 0.22 0.01 2.71% |
Momentum 39
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.12) | EPS Estimate Current Year (0.50) | EPS Estimate Next Year (0.39) | Wall Street Target Price 2.1667 | EPS Estimate Current Quarter (0.14) |
Using Adial Pharmaceuticals hype-based prediction, you can estimate the value of Adial Pharmaceuticals from the perspective of Adial Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Adial Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Adial because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Adial Pharmaceuticals after-hype prediction price | USD 0.21 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Adial Pharmaceuticals Basic Forecasting Models to cross-verify your projections. Adial Pharmaceuticals After-Hype Price Density Analysis
As far as predicting the price of Adial Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Adial Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Adial Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Adial Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Adial Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Adial Pharmaceuticals' historical news coverage. Adial Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.01 and 4.00, respectively. We have considered Adial Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Adial Pharmaceuticals is out of control at this time. Analysis and calculation of next after-hype price of Adial Pharmaceuticals is based on 3 months time horizon.
Adial Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Adial Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adial Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Adial Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.76 | 3.79 | 0.00 | 0.20 | 7 Events / Month | 5 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.22 | 0.21 | 0.00 |
|
Adial Pharmaceuticals Hype Timeline
Adial Pharmaceuticals is presently traded for 0.22. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.2. Adial is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is presently at -0.76%. %. The volatility of related hype on Adial Pharmaceuticals is about 1474.71%, with the expected price after the next announcement by competition of 0.02. The company has price-to-book (P/B) ratio of 1.36. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adial Pharmaceuticals recorded a loss per share of 0.6. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 7th of August 2023. Given the investment horizon of 90 days the next forecasted press release will be in about 7 days. Check out Adial Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Adial Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Adial Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Adial Pharmaceuticals' future price movements. Getting to know how Adial Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Adial Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| NRSN | Neurosense Therapeutics | 0.01 | 9 per month | 0.00 | (0.03) | 12.82 | (7.48) | 34.62 | |
| ACXP | Acurx Pharmaceuticals LLC | (0.56) | 14 per month | 0.00 | (0.18) | 10.84 | (9.84) | 49.19 | |
| MTNB | Matinas BioPharma Holdings | 0.02 | 6 per month | 0.00 | (0.15) | 11.67 | (10.67) | 39.32 | |
| BCLI | Brainstorm Cell Therapeutics | (0.01) | 8 per month | 0.00 | (0.02) | 9.09 | (6.67) | 24.01 | |
| APRE | Aprea Therapeutics | (0.39) | 8 per month | 0.00 | (0.27) | 4.40 | (8.43) | 17.87 | |
| HCWB | HCW Biologics | (0.13) | 9 per month | 0.00 | (0.23) | 13.02 | (11.97) | 41.72 | |
| KPRX | Kiora Pharmaceuticals | (0.32) | 8 per month | 0.00 | (0.05) | 5.32 | (5.58) | 16.69 | |
| CDIO | Cardio Diagnostics Holdings | (0.07) | 6 per month | 0.00 | (0.17) | 8.44 | (12.50) | 38.04 | |
| CELZ | Creative Medical Technology | (0.56) | 2 per month | 0.00 | (0.11) | 9.31 | (11.22) | 50.90 | |
| BCDA | Biocardia | (0.56) | 9 per month | 0.00 | (0.04) | 5.93 | (5.76) | 21.46 |
Adial Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Adial price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Adial using various technical indicators. When you analyze Adial charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Adial Pharmaceuticals Predictive Indicators
The successful prediction of Adial Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Adial Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Adial Pharmaceuticals based on analysis of Adial Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Adial Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Adial Pharmaceuticals's related companies.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Adial Pharmaceuticals Basic Forecasting Models to cross-verify your projections. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Adial Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Adial Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Adial's balance sheet. Smart investors calculate Adial Pharmaceuticals' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Adial Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Adial Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Adial Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.